<DOC>
	<DOCNO>NCT00289913</DOCNO>
	<brief_summary>This two-stage study evaluate immunogenicity , safety , tolerability administration VAQTA™ ( Hepatitis A Vaccine , Inactivated ) concomitantly PedvaxHIB™ ( Haemophilus B Conjugate Vaccine [ Meningococcal Protein Conjugate ] ) Infanrix™ ( Diphtheria Tetanus Toxoids Acellular Pertussis Vaccine Adsorbed , GlaxoSmithKline ) versus administration VAQTA™ healthy child 15 month age study entry .</brief_summary>
	<brief_title>Concomitant Use Hepatitis A Vaccine , Inactivated With Haemophilus b Conjugate Vaccine ( Meningococcal Protein Conjugate ) Diphtheria Tetanus Toxoids Acellular Pertussis Vaccine Adsorbed Given Healthy Children 15 Months Age ( V251-068 )</brief_title>
	<detailed_description>In stage I , VAQTA™ give concomitantly Infanrix™ and/or PedvaxHIB™ evaluate . In stage 2 : Two ( 2 ) dos VAQTA™ vaccine administer least 6 month apart . Safety data collect dose .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Stage 1 ) Healthy males female 15 month age active liver disease negative history hepatitis A vaccinated Haemophilus influenzae type b ( Hib ) , diphtheria , tetanus , pertussis disease Stage 2 ) Healthy males females 12 17 month age active liver disease negative history hepatitis A Stage 1 ) Males females previously vaccinate hepatitis A vaccine , immune deficiency , history allergy vaccine component , history seizure disorder neurologic disorder would contraindicate pertussis vaccine , bleed disorder Stage 2 ) Males females previously vaccinate hepatitis A vaccine , immune deficiency , history allergy vaccine component , history bleeding disorder</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>17 Months</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Hepatitis A virus</keyword>
</DOC>